TheLife Sciencesteam advised Korro Bio, Inc. ("Korro") (Nasdaq: KRRO) on entering into a subscription agreement for a private investment in public equity ("PIPE") financing that is expected to result in gross proceeds of approximately $85 million to Korro before placement agent fees and offering expenses. The PIPE financing was led by Venrock Healthcare Capital Partners and participation from new and existing investors, including ADAR1 Capital Management, Affinity Asset Advisors, Balyasny Asset Management, Driehaus Capital Management, Kalehua Capital, Lynx1 Capital Management, Nantahala Capital, and New Enterprise Associates. Pursuant to the terms of the subscription agreement, Korro is selling an aggregate of (i) 4,501,928 shares of its common stock at a purchase price of $11.11 per share and (ii) pre-funded warrants to purchase 3,148,836 shares of its common stock at a price of $11.109 per pre-funded warrant. The pre-funded warrants have an exercise price of $0.001 per share.
Korrois a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases. Korro is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process, enabling a precise yet transient single base edit. By editing RNA instead of DNA, Korro is expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability. Using an oligonucleotide-based approach, Korro expects to bring its medicines to patients by leveraging its proprietary platform with precedented delivery modalities, manufacturing know-how, and established regulatory pathways of approved oligonucleotide drugs. Korro is based in Cambridge, Massachusetts.
The Goodwin team was led byMarianne Sarrazin,Eunice Chang,Ari Kazanjian,andKingsley Taft.
For more information on the deal, please read thepress release.